Das Duttatrayee, Issac Anu Sumi, Sangala Bhavani N, Jerry Aldrin, Jankar Ajit, Jain Teerthesh, Singh Rohit Kumar
Department of Oral and Maxillofacial Pathology, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Patia, Bhubaneswar, Odisha, India.
Department of Pathology, Dr Somervell Memorial CSI Medical College, Karakonam, Trivandrum, Kerala, India.
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2555-S2557. doi: 10.4103/jpbs.jpbs_301_24. Epub 2024 Jul 31.
One of the main risk factors for the occurrence of oral cancer is oral precancerous lesions (OPLs). Early management and preventive efforts depend on knowing the transformation rate and detecting predictive signs of malignancy.
For 6 months, a group of 200 individuals with clinically diagnosed OPLs was followed up on in this longitudinal research. To examine biomarker expression levels and describe the lesions, examinations using immunohistochemistry, histopathology, and clinical methods were carried out.
Over the course of 2 years, 200 patients with OPLs were monitored in this study. Most lesions had mild dysplasia, according to histopathological examination. The expression of many biomarkers that were correlated with the dysplasia grade were p53 (60.0%), Ki-67 (40.0%), CDKN2A (30.0%), and epidermal growth factor receptor (EGFR) (25.0%).
In summary, this study emphasizes how crucial it is to provide patients with OPLs with individualized care plans and routine surveillance. Certain biomarkers, such EGFR, Ki-67, and p53, can be useful prognostic markers for identifying malignant transformation. To confirm these results and create tailored therapies for high-risk patients, more study is necessary.
口腔癌发生的主要危险因素之一是口腔癌前病变（OPL）。早期管理和预防措施取决于了解其转化率并检测恶性肿瘤的预测迹象。
在这项纵向研究中，对一组200例临床诊断为OPL的个体进行了为期6个月的随访。采用免疫组织化学、组织病理学和临床方法进行检查，以检测生物标志物表达水平并描述病变情况。
在本研究中，对200例OPL患者进行了为期2年的监测。根据组织病理学检查，大多数病变为轻度发育异常。与发育异常分级相关的多种生物标志物的表达情况为：p53（60.0%）、Ki-67（40.0%）、CDKN2A（30.0%）和表皮生长因子受体（EGFR）（25.0%）。
总之，本研究强调为OPL患者提供个性化护理计划和常规监测的重要性。某些生物标志物，如EGFR、Ki-67和p53，可作为识别恶性转化的有用预后标志物。需要更多研究来证实这些结果并为高危患者制定个性化治疗方案。
